A citation-based method for searching scientific literature

Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
Times Cited: 239



Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedlander, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray-Coquard, Susana Banerjee, Joyce Liu, Elizabeth S Lowe, Ralph Bloomfield, Patricia Pautier. Lancet Oncol 2017
Times Cited: 673




List of shared articles



Times cited

Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Ionut-Gabriel Funingana, Marika A V Reinius, Angelica Petrillo, Joo Ern Ang, James D Brenton. Semin Cancer Biol 2021
0

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Luigi Della Corte, Virginia Foreste, Claudia Di Filippo, Pierluigi Giampaolino, Giuseppe Bifulco. Expert Opin Investig Drugs 2021
0

Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
Tao Guo, Xue Dong, Shanli Xie, Ling Zhang, Peibin Zeng, Lin Zhang. Cancer Manag Res 2021
1

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Soledad Jorge, Andrew S McFaddin, Kemi M Doll, Kathryn P Pennington, Barbara M Norquist, Robin L Bennett, Colin C Pritchard, Elizabeth M Swisher. Gynecol Oncol 2020
6

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N Grisham, Paul J Goodfellow, Elise C Kohn, Douglas A Levine, Joyce F Liu, Karen H Lu,[...]. J Clin Oncol 2020
44

Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
Megan Rumford, Mark Lythgoe, Iain McNeish, Hani Gabra, Laura Tookman, Nazneen Rahman, Angela George, Jonathan Krell. Sci Rep 2020
4

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
William P Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael Bookman, Monica Brown Jones, Jung-Min Lee, Stéphanie Lheureux, Joyce F Liu,[...]. J Clin Oncol 2020
19

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.
Yizi Wang, Fang Ren, Zixuan Song, Xiaoying Wang, Chiyuan Zhang, Ling Ouyang. Front Oncol 2020
2

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Gulisa Turashvili, Conxi Lazaro, Shengjie Ying, George Charames, Andrew Wong, Krista Hamilton, Denise Yee, Evangeline Agro, Martin Chang, Aaron Pollett,[...]. Cancers (Basel) 2020
2

Current practices on genetic testing in ovarian cancer.
Florentia Fostira, Marios Papadimitriou, Christos Papadimitriou. Ann Transl Med 2020
0

PARP inhibitors in ovarian cancer.
Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura. Cancer Treat Rev 2019
75

Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Deborah Porto Cotrim, Adriana Regina Gonçalves Ribeiro, Daniele Paixão, Diogo Cordeiro de Queiroz Soares, Rima Jbili, Natasha Carvalho Pandolfi, Camila Cezana, Carine de Cássia Mauro, Henrique Mantoan, Graziele Bovolim,[...]. BMC Cancer 2019
6

Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
Elodie Chartron, Charles Theillet, Séverine Guiu, William Jacot. Crit Rev Oncol Hematol 2019
15

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
Robert D Morgan, George J Burghel, Nicola Flaum, Michael Bulman, Andrew R Clamp, Jurjees Hasan, Claire L Mitchell, Helene Schlecht, Emma R Woodward, Fiona I Lallo,[...]. J Med Genet 2019
10

Ovarian cancer relapse: From the latest scientific evidence to the best practice.
Daniela Luvero, Francesco Plotti, Alessia Aloisia, Roberto Montera, Corrado Terranova, Carlo De Cicco Nardone, Giuseppe Scaletta, Salvatore Lopez, Andrea Miranda, Stella Capriglione,[...]. Crit Rev Oncol Hematol 2019
9

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Jonathan A Ledermann, Eric Pujade-Lauraine. Ther Adv Med Oncol 2019
34

Olaparib in the treatment of ovarian cancer.
Christina R Washington, Debra L Richardson, Kathleen N Moore. Future Oncol 2019
7

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea.
Jun Hyeong Seo, Soo Young Jeong, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae,[...]. Obstet Gynecol Sci 2019
1

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date.
Lauren Montemorano, Michelle Ds Lightfoot, Kristin Bixel. Onco Targets Ther 2019
5

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
Jeanna M McCuaig, Tracy L Stockley, Patricia Shaw, Michael Fung-Kee-Fung, Alon D Altman, James Bentley, Marcus Q Bernardini, Beatrice Cormier, Hal Hirte, Katharina Kieser,[...]. J Med Genet 2018
18

Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.
Ena Arora, Muhammad Masab, Vishal Jindal, Iqra Riaz, Sorab Gupta, Gabor Varadi. Cureus 2018
2

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
Xiao Xia Guo, Hong Li Wu, Hong Yun Shi, Lei Su, Xi Zhang. Cancer Manag Res 2018
12